FDMT
4D Molecular Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$480.90M
P/E Ratio
—
EPS
$-2.42
Beta
2.93
52W High
$12.34
52W Low
$3.00
50-Day MA
$9.37
200-Day MA
$8.58
Dividend Yield
—
Profit Margin
-164.40%
Forward P/E
—
PEG Ratio
—
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Fundamentals
| Revenue (TTM) | $85.21M |
| Gross Profit (TTM) | $-107.29M |
| EBITDA | $-151.65M |
| Operating Margin | 17.40% |
| Return on Equity | -27.60% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $1.47 |
| Book Value | $8.78 |
| Price-to-Book | 0.95 |
| Price-to-Sales (TTM) | 5.64 |
| EV/Revenue | 1.188 |
| EV/EBITDA | -3.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 8509000.00% |
| Shares Outstanding | $51.05M |
| Float | $35.26M |
| % Insiders | 3.61% |
| % Institutions | 106.53% |
Historical Volatility
HV 10-Day
51.83%
HV 20-Day
53.66%
HV 30-Day
71.47%
HV 60-Day
66.59%
HV Rank
15.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.78 target)
1
Strong Buy7
Buy2
HoldData last updated: 4/29/2026